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ARTICLE
Mutations in FGD4 Encoding the Rho GDP/GTP Exchange Factor
FRABIN Cause Autosomal Recessive Charcot-Marie-Tooth Type 4H
Vale´rie Delague, Arnaud Jacquier, Tarik Hamadouche, Yannick Poitelon, Ce´cile Baudot,
Ire`ne Boccaccio, Eliane Chouery, Malika Chaouch, Nora Kassouri, Rosette Jabbour, Djamel Grid,
Andre´ Me´garbane´, Georg Haase, and Nicolas Le´vy
Charcot-Marie-Tooth (CMT) disorders are a clinically and genetically heterogeneous group of hereditary motor and sensory
neuropathies characterized by muscle weakness and wasting, foot and hand deformities, and electrophysiologicalchanges.
The CMT4H subtype is an autosomal recessive demyelinating form of CMT that was recently mapped to a 15.8-Mb region
at chromosome 12p11.21-q13.11, in two consanguineous families of Mediterranean origin, by homozygosity mapping.
We report here the identification of mutations in FGD4, encoding FGD4 or FRABIN (FGD1-related F-actin bindingprotein),
in both families. FRABIN is a GDP/GTP nucleotide exchange factor (GEF), specific to Cdc42, a member of the Rho family
of small guanosine triphosphate (GTP)–binding proteins (Rho GTPases). Rho GTPases play a key role in regulating signal-
transduction pathways in eukaryotes. In particular, they have a pivotal role in mediating actin cytoskeleton changes
during cell migration, morphogenesis, polarization, and division. Consistent with these reported functions, expression
of truncated FRABIN mutants in rat primary motoneurons and rat Schwann cells induced significantly fewer microspikes
than expression of wild-type FRABIN. To our knowledge, this is the first report of mutations in a Rho GEF protein being
involved in CMT.
From INSERM U491, Ge´ne´tique Me´dicale et De´veloppement, Faculte´ de Me´decine de la Timone (V.D.; T.H.; Y.P.; C.B.; I.B.; N.L.), and INSERM, Institut
de Neurobiologie de la Me´diterrane´e, Equipe AVENIR (A.J.; G.H.), Universite´ de la Me´diterrane´e, and Assistance Publique des Hoˆpitaux de Marseille,
De´partement de Ge´ne´tique Me´dicale, Hoˆpital d’enfants Timone (N.L.), Marseille, France; Unite´ de Ge´ne´tique Me´dicale, Universite´ Saint-Joseph (E.C.;
A.M.), and American University of Beirut Medical Center (R.J.), Beirut; Laboratoire de Biologie Mole´culaire, Institut Pasteur (T.H.), and ServicedeNeurologie,
Centre Hospitalier Universitaire Ben Aknoun (M.C.; N.K.), Algiers; and Ge´ne´thon III, Evry, France (D.G)
Received February 21, 2007; accepted for publication March 15, 2007; electronically published May 15, 2007.
Address for correspondence and reprints: Dr. Vale´rie Delague, INSERM U491, Faculte´ de Me´decine de la Timone, 27 boulevard Jean Moulin, 13385
Marseille CEDEX 05, France. E-mail: valerie.delague@medecine.univ-mrs.fr
Am. J. Hum. Genet. 2007;81:1–16.  2007 by The American Society of Human Genetics. All rights reserved. 0002-9297/2007/8101-0002$15.00
DOI: 10.1086/518428
Hereditary motor and sensory neuropathies (HMSNs),
commonly referred to as “Charcot-Marie-Tooth (CMT)
disease,” are among the most common inherited neuro-
logical diseases, with an overall prevalence of about 1–4/
10,000.1 Clinically, HMSNs are characterized by progres-
sive muscular and sensory defects starting at the distal
extremities, with chronic weakness, pes cavus, and loss of
deep tendon reflexes.2 Two main subgroups have been de-
fined on the basis of electrophysiological and histopath-
ological characteristics: the demyelinating form (CMT1)
and the axonal form (CMT2). CMT1 can be distinguished
from CMT2 by measuring motor nerve–conduction ve-
locities (NCVs): patients affected with CMT1 show re-
duced NCVs (38 m/s), whereas patients affected with
CMT2 show NCVs 38 m/s; the normal value is 48
m/s. Recently, a new group of CMT diseases with electro-
physiological and histopathological characteristics over-
lapping CMT1 and CMT2, referred to as “intermediate
CMT,” has been described.3
Genetically, CMT disease is characterized by a great het-
erogeneity4 (Neuromuscular Disease Center and Inherited
Peripheral Neuropathies Mutation Database). All modes
of inheritance have been reported. Autosomal recessive
demyelinating forms of CMT disease (CMT4) are less fre-
quent, usually of earlier onset, and more severe than the
autosomal dominant forms (CMT1), with a fast progres-
sion to severe disability leading to higher frequency of
wheelchair dependency in the life course.5
Among the 50 loci (30 genes) identified to date, 9 cor-
respond to CMT4, among which 6 genes have already been
identified: GDAP1 (MIM 606598)6,7 at chromosome 8q13-
q21.1 (CMT4A [MIM 214400])8; MTMR2 (MIM 603557)9
at chromosome 11q22 (CMT4B1 [MIM 601382])10; SBF2/
MTMR13 (MIM 607697)11,12 at chromosome 11p15
(CMT4B2 [MIM 604563 and MIM 607739])13; SH3CT2/
KIAA1985 (MIM 608206)14 at chromosome 5q23-q33
(CMT4C [MIM 601596])15; NDRG1 (MIM 605262)16 at
chromosome 8q24.3 (HMSN-Lom [MIM 601455])17; EGR2
(MIM 129010),18 P0 (MIM 159440),19,20 and PMP22 (MIM
601097)21 (CMT4E [MIM 605523] or Dejerine-Sottas syn-
drome [MIM 145900]); PRX (MIM 605725)22,23 at chro-
mosome 19q13.3 (CMT4F [MIM 605725]24 and Dejerine-
Sottas syndrome); HMSN-Russe (MIM 601455) at chro-
mosome 10q22-q23,25 for which no corresponding mu-
tated gene has yet been identified; and, finally, CMT4H
(MIM 609311), which we recently assigned to chromo-
some 12p11.21-q13.11.26
The roles and function of proteins involved in autoso-
mal recessive CMT (AR-CMT) disease are diverse, includ-
ing proteins involved in polyposphoinositide signal-
ing27 (myotubularins MTMR2 and MTMR13), mitochon-
drial fission proteins (GDAP1),28 structural myelin pro-
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Figure 1. Pedigrees of the Lebanese (500) and Algerian (295) families. Blackened symbols indicate affected individuals.
teins like periaxin (L-PRX), proteins involved in growth
arrest and cell differentiation (NDRG1), and proteins
with no known function (SH3CT2/KIAA1985). Moreover,
several proteins related to GTPase signaling have been
identified in CMT disease: mitofusin 2 (MFN2),29 dynamin
2 (DNM2),30 RAB7,31 ARHGEF10,32 and SEPT9.33 Rho
GTPases are molecular switches that control a wide variety
of signal-transduction pathways in eukaryotic cells, in-
cluding regulation of the actin and microtubule cytoske-
leton and cell polarization, migration, and prolifera-
tion.34,35 Along with GTPase-activating proteins (GAPs)
and guanine nucleotide dissociation inhibitors (GDIs),
Rho GDP/GTP nucleotide exchange factors (Rho GEFs) are
essential regulators of Rho GTPases. About 1% of the hu-
man genome encodes proteins that either regulate or are
regulated by direct interactions with members of the Rho
family small GTPases, and more than 85 Rho GEFs, reg-
ulating 22 GTPases, are known to date.34 In this article,
we report the identification of mutations in FGD4 en-
coding FGD4/FRABIN (FGD1-related F-actin binding pro-
tein [GenBank accession number NP_640334]) in two fam-
ilies from Algeria and Lebanon with members affected
with CMT4H. FRABIN is a GEF specific to Cdc42, a mem-
ber of the Rho family of small GTP-binding proteins (Rho
GTPases).36,37
Consistent with these reported functions, expression of
truncated FRABIN mutants in rat primary motoneurons
and rat Schwann cells induced significantly fewer mi-
crospikes than expression of wild-type FRABIN. In all, FRA-
BIN is the sixth protein related to GTPase signaling but
the first Rho GEF to be identified in CMT disease.
Material and Methods
Patients
We previously published the localization of CMT4H from one
Lebanese family and one Algerian family with CMT4H.26 Patients
are affected with early-onset demyelinating neuropathy. For de-
tailed clinical, electrophysiological, and histological descriptions
and data, see the work of De Sandre-Giovannoli.26 After informed
consent was obtained from all individuals and parents of children
included in this study, EDTA blood samples were collected, and
genomic DNA was extracted from lymphocytes with the use of
standard methods. In all, 29 DNA samples were collected for the
study, including 10 from affected individuals (fig. 1). Biopsies of
skin and sural nerve samples were performed in Lebanese patient
500.21 under local anesthesia after informed consent was ob-
tained from his parents. All protocols performed in this study
complied with the ethics guidelines of the institutions involved.
Mutation Analysis
Exploration of the entire coding sequence of candidate genes
(KIF21A [GenBank accession number AY368076], RAPGEF3
[GenBank accession number U78168], and FGD4 [GenBank ac-
cession numbers AK057294, BC045552, and AY367054]) was per-
formed in Lebanese patient 500.21 and Algerian patient 295.3
(fig. 1). Intronic primers were designed using Primer3 software.
DNA sequences were obtained from the UCSC Genome Browser
(May 2004 freeze), by comparison of genomic DNA with cDNA
sequences. For FGD4, six additional alternatively spliced exons
described in other sequences from the UCSC database were
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Table 1. Primer Sequences and Annealing Temperatures for FGD4 Analysis of Coding Sequences at
the Genomic and Transcriptional Level
Analysis and Amplicon
Primer Sequence (5′–3′)
Amplification
Product Size
(bp)
Optimal
Annealing
Temperature
(C)Forward Reverse
Genomic DNA:
Exon 1 gccttaggagggctggttac gataatgcccccacacaaac 296 56
Exon 2 cctgccctttctttctgaac gtggccatcatttttctggt 258 56
Exon 3 cacccaggacaccagaattt cctgccttctcccattgtaa 292 54
Exon 4a ccaatgttttcatgcttcctt tgagctaagagtggcagcttt 282 56
Exon 4b ctcagggtgcacagacttgt cagggttttccctgctcat 395 55
Exon 5 gatggctgaaagaaccgagt aaaacaggcccttccttcat 329 55
Exon 6aa ccactgctgctgacctttta aaaacaaaaacccaaaccttca 257 55
Exon 6 gagcccactatgtgcctagc cagcatgactgccttaaaca 272 56
Exon 7 gccactgcactacagtctgg ggagtagaatgaattttggctagg 370 60
Exon 8 tcatgcaggtgatggacagt gaaaccataaggctgcttgg 337 56
Exon 9 gcacaggaaggacaaagcat ttcataaacattctttttggctca 234 56
Exon 10 tgcctgtatgtgatcttgctg ctcccaaagtgctgggatta 277 60
Exon 11 cctgatcagtttcccctatttc gttgcctgattttggaaagc 275 56
Exon 12 agttggaacaacaggaaagca cagacagaggctgcagtgag 231 56
Exon 12ab gcctcttgagtagctgggact tgaaaattaagtgaacctgttctga 291 55
Exon 13 tgagaaactttaatgtgtgctttga gggaaaaggttggagaacaa 228 56
Exon 14 tccgaaagtgctgggattat cgtaattggcaccaaaataaa 383 …
Exon 15 caaaaatctgccttctatgctt ttgcagtgagctgagatcgt 363 59
Exon 15ab gaggctgaggcaggagaat cccagaacagagcctgaactt 596 …
Exon 16c tttggatagtccagggaaaca attttgagtccgctgtccac 325 56
Exon 17 ctgtttgggacagtggtagga tcctgagacctccacaccat 398 56
Exon 18b ggacacacttaagttttggctca gactgctcaagtatgttggaagg 393 55
Exon 19b tgatttgcaattctgtctttcc gaccatgattgacttcagattttt 493 55
RT-PCR:
Exon 5–exon 8 gcaaactgttggaagaagca agggaatcaggaggcaattt 412 55
Fragment 1 tcgctttagttccaccttgc tccttcatctcatggtgctg 826 59
Fragment 2 ctacaggactccaggcatagg tgaagtgttccgagcagcta 850 60
Fragment 3 gattccctggactggaatga gaagaaagctgcaca 847 59
Fragment 4 aaaagagccccaagatggat tgcatttatgggcctatatttt 768 55
RTQ-PCR:
FGD4 (exon 2) tcagatctcatcagtcgctttg acagcagactctttcttcaaatca 74 …
TBP (reference gene 1) gctggcccatagtgatcttt cttcacacgccaagaaacagt 60 …
GUSB (reference gene 2) cgccctgcctatctgtattc tccccacagggagtgtgtag 95 …
Mouse RT-PCRd:
Exon 4–exon 8 atgggattggatacgttgga aggaatgcgctgaataggc 498 60
NOTE.—Specific primers for RTQ-PCR are also mentioned. All human primers for genomic screening of mutations were
selected on the basis of comparison of genomic DNA sequence with GenBank cDNA sequence AK057294. Exon 4 was
amplified in two amplicons (4a and 4b).
a Alternatively spliced exons found in GenBank sequence BC045552.
b Alternatively spliced exons found in GenBank sequence AY367054.
c For the longer exon 16 in sequence BC045552, we used reverse primer 5′-gaaaggggacagatgatcca-3′ and an annealing
temperature of 55C.
d Primers were designed using GenBank sequence NM_139234.
screened for mutations: exons 6a and 16b are present in GenBank
sequence BC045552, and exons 12a, 15a, 18, and 19 are present
in GenBank sequence AY367054. Primer sequences and anneal-
ing temperatures used in PCRs for FGD4 are described in ta-
ble 1. Those used for KIF21A and RAPGEF3 are available on re-
quest. Genomic DNA was amplified for one patient of each family
under standard PCR conditions. All PCR-amplified fragments
were analyzed by denaturing high-performance liquid chroma-
tography (dHPLC)/WAVE (Transgenomic) and were fluorescently
sequenced in both directions for those presenting abnormal elu-
tion profiles, with the use of sequencing facilities (MWG Biotech).
Conditions for dHPLC analysis are available on request. Chro-
matograms were compared with reference sequences with the use
of Sequencher v4.2 (Gene Codes). The identified c.893TrG and
the C.893TrC genomic variants were tested in 216 Lebanese and
108 Algerian control chromosomes by restriction endonuclease
digestion with the use of MlnII and MaeII (New England Biolabs),
respectively.
Transcriptional Analysis
Total RNA was extracted from freshly isolated lymphocytes with
the use of either TRIZOL (Invitrogen Life Technologies), on the
basis of protocol derived from the work of Chomozynsky and
Sacchi,38 or silica-gel RNeasy colums (QIAGEN). cDNAs were ob-
tained from total RNA with use of Superscript I Reverse Tran-
scriptase (Invitrogen Life Technologies) and random primers (In-
vitrogen Life Technologies), in accordance with the recommen-
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dations of the supplier. cDNAs were then PCR amplified as de-
scribed above. Primers and annealing temperatures are described
in table 1. RT-PCR experiments, which gave rise to several frag-
ments, were cloned into PGEM Vector (PROMEGA), in accordance
with the supplier’s instructions, and were transformed by elec-
troporation into electrocompetent Escherichia coli cells. Positive
clones were selected and amplified by PCR, and fragments were
subsequently sequenced as described above.
Real-Time RT-PCR
SYBR Green real-time PCRs (RTQ-PCRs) were realized according
to standard protocols in a 20-ml final volume, with the use of
primers at a final 500 mM concentration on a Lightcycler 480
(Roche). Of the RNAse H–treated (Invitrogen Life Technologies)
cDNAs obtained from reverse transcription of DNAse I–treated
total RNA extracted from cultured fibroblasts by use of the High
Capacity cDNA Archive Kit (Applied Biosystems), 50 ng were used
in each reaction. The expression level of FGD4 was normalized
to that of two different genes: TBP (TATA-box binding protein)
and GUS-B (b-glucuronidase). Two calibrator samples (normal fi-
broblast cell lines) were used, and experiments were repeated
three times. The FGD4 expression ratio for a sample was calcu-
lated as the ratio between the average FGD4 signal in the patient’s
fibroblast and the signal from calibrators. Primer sequences can
be found in table 1.
Expression Studies
One microgram of each used commercial total RNAs extracted
from brain, heart, skeletal muscle, uterus and cerebellum (Am-
bion-Applied Biosystems), placenta and testis (Clontech) were
used in RT-PCRs as described above. Primers located in exons 5
(forward) and 8 (reverse) of FGD4 were used for PCR amplifica-
tion, which resulted in a 412-bp fragment (see table 1). b-actin
was used as a control for normalization with the use of primers
5′-CAATAGTGATGACCTGGCCGT-3′ (forward) and 5′-AGAGGG-
AAATCGTGCGTGAC-3′ (reverse).
FGD4 expression in different mouse parts of the brain and CNS
tissues was studied by use of the ORIGENE Mouse Brain Rapid-
Scan Panel. cDNAs obtained from polyA RNAs immobilized on
a 96-well plate were amplified using either the aforementioned
FGD4 primers (table 1) or b-actin control primers, with the use
of PCR conditions recommended by the supplier.
Expression Constructs
The cDNA for rat wild-type Frabin-GFP was isolated from the
pMXII Frabin-GFP plasmid kindly provided by Prof. Takai and
was subcloned into an XhoI-restricted pCAGGS expression vec-
tor.39 Truncated forms of Frabin were obtained by PCR (Triple
master), with the use of pCAGGS Frabin-GFP as template and
forward primer Frabin Fw NheI (5′-AAGGAAACTA GCTAGC ACC-
ATGGAGGAGTCTAATCC-3′) together with reverse primer Frabin
Rev 297 Not1 (5′-TTCCTTTTTT GCGGCCGC CTTAAGGAATGGT-
GCCAAC-3′) or Frabin Rev 249 Not1 (5′-TTCCTTTTTT GCGGC-
CGC CATCTCTGCAGGAAATGAGCCTC-3′) (underlined parts of
sequences correspond to endonuclease restriction sites). PCR
products were subcloned into pCAGGS-GFP 5′ of the GFP reading
frame. The obtained constructs were checked by sequencing.
Cell Culture
Spinal motoneurons were prepared from E14.5 Sprague Dawley
rat embryos as described elsewhere.40 Cell pellets were resus-
pended in electroporation buffer (125 mM NaCl, 5 mM KCl, 1.5
mM MgCl2, 10 mM glucose, and 20 mM HEPES [pH 7.4]) at a
density of 50,000 motoneurons per 50 ml and were transferred to
4-mm gap cuvettes (Eppendorf). The cellular suspensions were
then incubated for 15 min at room temperature with 5 mg p-
CAGGS GFP plasmid or the same molar amount of pCAGGS Fra-
bin expression plasmid and were electroporated using a BTX-
ECM830 electroporator (Genetronics). Electroporation condi-
tions were 3 square pulses of 5 ms at 200 volts with intervals of
1 s. Motoneurons were cultured on polyornithin/laminin–coated
coverslips in supplemented neurobasal medium (Invitrogen Life
Technologies) containing 1 ng/ml GDNF, 1 ng/ml BDNF, and 10
ng/ml CNTF.
Primary human fibroblasts and RT4 schwannoma cells were
cultured in Dulbecco’s modified Eagle medium (DMEM) (Invitro-
gen Life Technologies) supplemented with 10% fetal calf serum
(Invitrogen Life Technologies) and L-glutamine in a 37C incu-
bator stabilized at 5% CO2. RT4 cell lines are described to be
arguably equivalent to primary Schwann cells in vitro.41
Immunostaining and Microscopy
Transduced primary motoneurons and RT4 Schwann cells were
fixed at 1 division (DIV) with 4% (vol/vol) formaldehyde, were
washed three times with PBS, and were blocked and permeabil-
ized with PBS containing 2% (vol/vol) goat serum, 2% (vol/vol)
donkey serum, 0.1% (wt/vol) BSA, 50 mM lysine, and 0.01% (vol/
vol) Triton X-100. F-actin was stained for 30 min with Alexa Fluor
546-conjugated phalloidin (diluted 1:80 in blocking buffer [Mo-
lecular Probes]). Images of GFP–fluorescent cells were acquired
with a Zeiss LSM 510 confocal laser scanning microscope that
used a 63# water immersion objective and 3# zoom for mo-
toneurons or 1# zoom for RT4 cells.
In motoneuron cultures, the number of microspikes was de-
termined per individual transduced cell ( neurons per con-np 25
dition). In RT4 Schwann cell cultures, microspike formation was
expressed as the percentage of transduced cells bearing more than
10 f-actin–positive protrusions at their peripheries.37 Per condi-
tion, 1100 transduced RT4 cells were analyzed. Statistical analyses
were performed using SigmaStat software (Systat).
At 90% confluency, fibroblast cultures were treated with tryp-
sin-EDTA (0.05% trypsin and 0.53 mM EDTA.4Na [Invitrogen Life
Technologies]). After they were counted, 105 cells were plated on
2-well Lab Tek Chamber slides (Nalge Nunc International) and
were cultured in DMEM, high-glucose medium supplemented
with 10% calf serum, 2 mM L-glutamine, and a mix of penicillin-
streptomycine-fungizone. After 24 h of growth in a 37C incu-
bator stabilized at 5% CO2, cells were washed twice in Dubelcco’s
PBS and were fixed in 4% paraformaldehyde.
Cells were then washed for 10 min in PBS and were permea-
bilized with 0.5% Triton X-100 in PBS for 5 min at room tem-
perature. After they were blocked for 1 h at room temperature in
PBS containing 1% BSA, cells were incubated with primary an-
tibodies diluted in the incubation solution for 1 h at room tem-
perature. Primary antibodies used in this study were mouse
monoclonal to actin (Chemicon), mouse monoclonal to g-tub-
ulin (clone GTU-38 [SIGMA]), rabbit polyclonal to pericentrin
(abcam), rabbit polyclonal to a-tubulin (abcam), mouse mono-
clonal to a-tubulin (clone B-5-1-2 [abcam]), and mouse mono-
Figure 2. CMT4H locus, structure of FGD4 and FRABIN, mutations, and conservation between species. A, Chromosomal region at
12p11.21-q13.11 containing the CMT4H candidate locus, as identified elsewhere,26 covering a 15.8-Mb region located between STR
markers D12S1648 and D12S1661. STR markers homozygous by descent are shown in red. The 48 known genes lying in this region are
schematically represented, with candidate genes tested in our study indicated in red (FGD4, CNTN1, KIF21A, and RAPGEF3). B, Structure
of FGD4. The gene is located at 12p11.21, near the centromere, and is transcribed from telomere to centromere, as indicated by the
black arrow. The gene, covering a genomic region of 138,580 bp, as defined by the GenBank reference sequence NM_139241, is composed
of 17 exons. The transcript is 2,931 bp long, with a coding sequence (exons 3–17) of 2,301 bp (for mRNA [GenBank accession number
AK057294]). The coding region is indicated in gray and UTRs (5′ and 3′) in white. The coding sequence includes exons 3–17. Additional
exons found in alternative splice variants are described in the databases but are not represented here. C, Five functional domains
presented by FRABIN, encoded by FGD4: FAB, DH presenting a Rho GEF activity, PH1 and PH2, which bind to phosphatidylinositol(3,4,5)P3,
and one FYVE domain that interacts with phosphatidylinositol3P. D, Chromatograms showing the two mutations identified in FGD4: the
c.893TrG transversion in the Lebanese patients and the c.893TrC transition in the Algerian patient. E and F, The methionine at residue
298, mutated in both patients, which is highly conserved in different species (vertebrates and nonvertebrates), as well as in other
members of the human FGD family.
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Figure 3. The c.893TrG splicing mutation. A, Results of RT-PCR experiments performed on the Lebanese patient’s fibroblasts and
peripheral nerve (PN) and in the control fibroblasts, with use of a forward primer located in exon 5 and a reverse primer located in
exon 8 (see table 1). In control fibroblasts, a 412-bp band corresponding to the wild-type transcript was obtained. In the Lebanese
patient’s fibroblasts, we observed two additional bands corresponding to transcripts 1 and 2 described in panel B. In fibroblasts, a
band the size of the wild-type transcript was observed, corresponding to the correctly spliced transcript with a homozygous p.Met298Arg
missense mutation. B, Schematic representation of splicing defects caused by the c.893TrG Lebanese mutation observed in panel A.
In the first mutant (transcript 1), the GT donor splice site created by the mutation was used instead of the usual consensus 5′ donor
site. The transcript deleted from the last 100 bp of exon 7 is predicted to yield a 305-aa truncated protein, and the mutation is
described as “p.Met298fsX8.” In transcript 2 (224 bp), in addition to the last 100 bp of exon 7, the last 99 bp of exon 6 are deleted
because of the use of a cryptic donor splice site in exon 6. Transcript 3, identified after the cloning of RT-PCR fragments obtained from
the patient’s lymphoblast cDNA, lacks the last 99 bp of exon 6 and all of exon 7.
clonal to acetylated tubulin (clone 6-11B-1 [SIGMA]), diluted, re-
spectively, at 1:100, 1:1,000, 1:2,000, 1:100, 1:1,000, and 1:
2,000. After several washes in PBS, slides were incubated with
secondary antibodies diluted in the incubation solution for 1 h
at room temperature. Secondary antibodies were from either
Jackson (Jackson ImmunoResearch: FITC-conjugated Rabbit an-
tibody against Mouse [1:100], TRITC-conjugated Donkey anti-
body against Rabbit [1:100], and FITC-conjugated Goat antibody
against Mouse) or Molecular Probes (Invitrogen: Alexa Fluor 488
Goat antibody against Mouse or Goat antibody against Rabbit
and Alexa Fluor 555 Goat antibody against Mouse or Goat an-
tibody against Rabbit). Cells were then washed three times for 10
min in PBS, were incubated with DAPI (Sigma-Aldrich) at 100 ng/
ml for 15 min, and finally were washed three times in PBS. Slides
were mounted in Vectashield mounting medium (Vector), were
coverslipped, and were sealed. Digitized microphotographs were
recorded using a Leica DMR microscope (Leica Microsystems)
equipped with a CoolSNAP camera (Princeton).
Results
We studied two large consanguineous families affected
with CMT4H and originating from Algeria and Lebanon
(fig. 1). By use of homozygosity mapping in these families,
the locus for CMT4H was previously assigned26 to a 15.8-
Mb (11.5-cM) region at chromosome 12p11.21-q13.11,
between markers D12S1648 and D12S1661, with a max-
imum LOD score value of 6.97 ( ) at markervp 0.001
D12S345. Screening of the coding sequence of several
genes (PRPH, CNTN1, RAPGEF3, KIF21A, and FGD4) lying
in the candidate interval (fig. 2A), by direct sequencing,
allowed us to identify FGD4, encoding FGD4/FRABIN, as
a strong candidate (fig. 2B and 2C). Indeed, two homo-
zygous missense variations were found in the two initially
linked families: a c.893TrG transversion and a c.893TrC
transition in the Lebanese and Algerian families, respec-
tively (fig. 2D). Both mutations segregated perfectly with
the phenotype in each pedigree and affected the same
nucleotide in FGD4 exon 7. These sequence variations
were not found in 216 Lebanese or 108 Algerian control
chromosomes and were thus considered to be disease-
causing mutations. Multiple alignment of FRABIN with
Frabin orthologs from vertebrates and invertebrates in-
dicated that both mutations target a highly conserved
amino acid residue (fig. 2E) through evolution. A specific
alignment of FRABIN with the four known members of
the FGD Rho GEF family in human also demonstrates a
perfect conservation of the methionine at position 298
(fig. 2F).
With use of total RNA extracted from lymphoblastoid
cell lines or fibroblasts, FGD4 full-length cDNAs were am-
plified by RT-PCR in patients from both families. In the
Algerian patient (295.6) (fig. 1), no abnormal transcript
could be identified, which likely ruled out a possible splic-
ing defect associated with this specific mutation and fur-
ther indicated that the c.893CrT transition is likely to be
a missense mutation leading to the replacement of a me-
thionine by a threonine at codon 298 (p.Met298Thr) (fig.
2D). Conversely, in the Lebanese patient (500.21) (fig. 1),
transcripts at a size lower than expected were retrieved,
which suggested an associated splicing defect (fig. 3A).
Indeed, further sequencing revealed a transcript (tran-
script 1) lacking the last 100 bp of exon 7, resulting from
the use of an upstream donor splice site created by the
c.893TrG mutation at codon 298 in exon 7, instead of
the usual natural consensus 5′ donor site (fig. 3B). The
c.893TrG mutation, initially predicted to be a missense
p.Met298Arg mutation, is consequently also a splicing
mutation predicted to likely result in a truncated protein
of 305 aa instead of 766 aa (p.298MetfsX8) (fig. 3B). Per-
sistence of the mutated full-length transcript was observed
in the patient’s fibroblasts, whereas it was completely ab-
sent in the patient’s peripheral nerve (fig. 3A). Addition-
ally, two other transcripts were also identified in this pa-
tient (fig. 3A and 3B): transcript 2, which lacked the last
99 bp of exon 6 in addition to the last 100 bp of exon 7,
because of the use of a cryptic donor splice site in exon
6, and transcript 3, identified after cloning of RT-PCR
fragments obtained from the patient’s lymphoblast cDNA,
in which the last 99 bp of exon 6 and all of exon 7 are
deleted (fig. 3B). For transcript 2, two homologous ESTs
from different species lacking the end of exon 6 were
found in the databases (GenBank accession number
AA305646 for Homo sapiens and GenBank accession num-
ber CN643653 for Macaca mulatta), suggesting that it
might be a naturally produced alternative transcript and
that we describe here a mutant form of this transcript.
This transcript would encode a 253-aa truncated protein.
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Transcript 3 was not reported in the databases and might
either be produced by the mutation or be another tissue-
specific alternative transcript. The predicted protein would
harbor an 81-aa inframe deletion in the Dbl homology
(DH) domain.
Finally, in the course of full-length cDNA amplifica-
tion, two other splice variants were identified, neither of
which corresponded to the C-terminal splice variants of
Frabin described in mouse (GenBank accession number
NP_631978).42 In the first one, described in the databases,
the entire initiation codon containing exon 3 is deleted.
Removal of exon 3 leads to absence of the known AUG
initiation codon. ORF predictions (National Center for
Biotechnology Information ORF Finder) predict the use of
a downstream AUG at codon 94 of the normal protein
FRABIN that would lead to a 673-residue protein identical
to FRABIN, but deprived of the first FAB domain. The sec-
ond alternative transcript, produced by a mechanism sim-
ilar to the one described in exon 6 for transcripts 2 and
3, leads to the deletion of the last 54 bp of exon 16. The
predicted protein would present an 18-aa inframe deletion
within the PH2 domain.
Transcriptional studies were conducted by RTQ-PCR
with the use of RNAs extracted from fibroblasts of the
Lebanese patient and controls (fig. 4A). This showed a 60%
reduction in FGD4 mRNA levels, indicating that the trun-
cated mRNA might be degraded through nonsense-me-
diated mRNA decay (NMD) and that the corresponding
protein might not be produced. Unfortunately, a polyclo-
nal antibody against FRABIN generated in rabbit but failed
to detect FRABIN in control tissues (data not shown).
FGD4 is known to be ubiquitously expressed, at least in
all tested tissues.37 In this study, we have also detected its
expression in different human tissues including peripheral
nerve (figs. 3A and 4B). Additionally, we checked the Fgd4
expression pattern in mouse nerve tissues at different
stages of development and demonstrated that it was ex-
pressed in all parts of the brain and in the spinal cord at
embryonic, postnatal, and adult stages (fig. 4C). Interest-
ingly, levels of expression were lower in postnatal and
adult tissues than in embryonic tissues.
To further explore the functional consequences of the
truncating mutation identified, we analyzed, by confocal
microscopy, embryonic rat spinal motoneurons and rat
RT4 schwannoma cells after transfection with expression
vectors encoding GFP-tagged forms of either wild-type rat
Frabin (GenBank accession number NP_640356) or trun-
cated forms of Frabin corresponding to p.M298fsX8 (fig.
5A). In electroporated rat motoneurons, wild-type full-
length Frabin (i) colocalized with phalloidin-stained f-ac-
tin in neurite tips and growth cones (not shown), in line
with previous data obtained in other cell types,36,37,43,44 and
(ii) induced the formation of filopodia-like microspikes
(fig. 5B). Expression of full-length Frabin resulted in a 3.75-
fold increase in the mean number of microspikes per mo-
toneuron as compared with GFP-expressing motoneurons
(fig. 5B and 5C). When the truncated forms of Frabin were
expressed in motoneurons, they still colocalized with f-
actin but induced significantly fewer microspikes than did
full-length Frabin (fig. 5B and 5C). Moreover, the remain-
ing microspikes acquired an abnormally curled shape (fig.
5B). Similar results were observed in rat RT4 schwannoma
cells, in which the expression of wild-type full-length Fra-
bin induced formation of microspikes, whereas the ex-
pression of truncated Frabin significantly inhibited this
effect (fig. 6).
FRABIN is a GEF specific for Cdc42, a Rho GTPase in-
volved in the reorganization of not only actin micro-
filaments but also the microtubule cytoskeleton.34,45 We
consequently tested whether the microfilament (actin-
labeling) or microtubule (a-tubulin and acetylated a-tub-
ulin) cytoskeleton or centrosome (g-tubulin) was disor-
ganized in patient fibroblasts as compared with control
fibroblasts. We did not observe any significant abnormal-
ities of the microfilaments or in the distribution and or-
ganization of the microtubules (fig. 7).
Discussion
CMT diseases are a clinically and genetically heteroge-
neous group of HMSNs, with 50 loci and 30 genes iden-
tified to date. These genes encode proteins of various func-
tions: myelin structural proteins; transcription factors
involved in myelin gene regulation; proteins involved in
protein-sorting synthesis or degradation, transport pro-
cesses, cytoskeleton and mitochondrial dynamics.46 In this
study, we report two mutations in FGD4—the gene en-
coding FRABIN, an F-actin Rho GEF specific to Cdc4236,
37—in patients affected with CMT4H, an autosomal re-
cessive form of demyelinating CMT disease. This 766-aa
protein is composed of five functional domains: an N-
terminal F-actin binding (FAB) domain, one Dbl homol-
ogy (DH) domain, two pleckstrin homology (PH) domains,
and one cysteine-rich FYVE domain36 (fig. 2C). DH do-
mains were first identified in the Dbl protein and are pre-
sent in many proteins, where they play a key role in the
catalysis of GDP-to-GTP exchange,47 whereas PH and FYVE
domains are mainly involved in interactions with differ-
ent forms of phosphoinositides.48,49
Both mutations in FGD4 described here modify the
same nucleotide and affect an evolutionarily highly
conserved amino acid residue at position 298 of the FRA-
BIN protein, indicating functional relevance. As this res-
idue lies within the DH domain, responsible for Cdc42
activation, we might postulate that the mutations de-
scribed here affect or prevent Cdc42 activation, although
through different mechanisms. In the Algerian family, the
p.Met298Thr mutation might change the conformation
of the domain and prevent binding to Cdc42. In the Leb-
anese family, the p.Met298Arg mutation is in fact a splic-
ing mutation predicted to result in a truncated protein
(p.Met298fsX8) lacking not only the terminal part of the
DH domain and the first PH domain, which, together with
the FAB domain, have been shown to be necessary for
Figure 4. Expression analysis. A, RTQ-PCR experiments with use of cDNAs extracted from the patient’s fibroblasts and two controls.
TBP was used as the reference gene for normalization. An approximate average twofold underexpression of FGD4 was observed in Lebanese
patients with CMT4H as compared with calibrators ( , Wilcoxon-Mann-Whitney test). Similar results were obtained using normal-P ! .05
ization with GUSB (data not shown). B, Semiquantitative expression of FGD4 in different human adult tissues. b-actin was used for
normalization. C, Expression of FGD4 in different mouse nerve tissues. Two cDNA concentrations were used (100# and 1,000#). b-
actin was used for normalization. Lanes (L) correspond to the following: L1, embryo day 13 (E13) telencephalon/diencephalons. L2,
E13 mesencephalon (midbrain). L3, E13 rhombencephalon (hindbrain). L4, E13 spinal cord. L5, E15 telencephalon. L6, E15 diencephalon.
L7, E15 midbrain. L8, E15 pons. L9, E15 medulla. L10, E15 spinal cord. L11, E18 frontal cortex. L12, E18 posterior cortex. L13, E18
entorhinal cortex. L14, E18 olfactory bulb. L15, E18 hippocampus. L16, E18 striatum. L17, E18 thalamus. L18, E18 hypothalamus. L19,
E18 midbrain. L20, E18 pons. L21, E18 medulla. L22, E18 spinal cord. L23, postnatal day 7 (P7) frontal cortex. L24, P7 posterior cortex.
L25, P7 entorhinal cortex. L26, P7 olfactory bulb. L27, P7 hippocampus. L28, P7 striatum. L29, P7 thalamus. L30, P7 hypothalamus.
L31, P7 cerebellum. L32, P7 midbrain. L33, P7 pons. L34, P7 medulla. L35, P7 spinal cord. L36, adult 5-wk (A5) frontal cortex. L37,
A5 posterior cortex. L38, A5 entorhinal cortex. L39, A5 olfactory bulb. L40, A5 hippocampus. L41, A5 striatum. L42, A5 thalamus. L43,
A5 hypothalamus. L44, A5 cerebellum. L45, A5 midbrain. L46, A5 pons. L47, A5 medulla. L48, A5 spinal cord. FGD4 was expressed in
all parts of the brain and in spinal cord, but with stronger expression at embryonic and prenatal stages than at postnatal and adult
stages.
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Figure 5. A, Domain organization of rat Frabin constructs. Frabin FL GFP p full-length Frabin C-terminally tagged to GFP. Frabin 1–
297 GFP p GFP-tagged Frabin lacking the last 469 aa, mimicking the predicted protein resulting from mutant transcript 1 (see fig. 3);
Frabin 1–249 GFP p GFP-tagged Frabin lacking the last 513 aa, mimicking the protein corresponding to mutant transcript 2 (see fig.
3). B, Confocal images of rat motoneurons transduced with GFP or GFP-tagged Frabin expression constructs and labeled at 1 DIV for
f-actin using Alexa Fluor 546-conjugated phalloidin. While GFP shows uniform cytoplasmic expression, FL Frabin GFP colocalizes with
f-actin in microspikes and induces their formation (see merged images and insets). Note reduced number and abnormal shape of
microspikes induced by expression of truncated Frabin constructs. Scale barp 10 mm. C, Diagram showing reduced microspike formation
in motoneurons expressing truncated forms of Frabin as compared with motoneurons expressing full-length Frabin ( cells pernp 25
condition, as assessed by Mann-Whitney rank sum test).P ! .001
Cdc42 activation,43 but also the second PH and FYVE do-
mains, which, together with the DH domain and the first
PH domain, are necessary for c-Jun N-terminal kinase
(JNK) activation37 and bind to polyphosphoinositides.36
JNK is a member of the stress-activated protein kinases
family, a type of mitogen-activated protein kinases de-
scribed in brain as “microtubule-associated protein ki-
nases” for their phosphorylation of microtubule-associ-
ated proteins and other neuronal cytoskeletal proteins. It
is one of the key factors involved in morphogenesis in
various multicellular organisms and regulates planar cell
polarity, cell migration, and apoptosis.50 Suppression of
JNK activation due to the p.Met298fsX8 mutation might
consequently perturb Schwann cell morphology, polarity,
or proliferation or might lead to a lack of activation of
transcription factors required for myelination, thus caus-
ing aberrant myelination in peripheral nerves. Addition-
ally, in mouse nerve tissues, we found that Fgd4 was ex-
pressed in all parts of the brain and in the spinal cord at
embryonic, postnatal, or adult stages. Interestingly, levels
of expression are lower in postnatal and adult tissues than
in embryonic tissues.
This result, together with the facts that FRABIN activates
JNK36 and that the JNK pathway is inhibited at the onset
of myelination,51 suggests that FGD4 might have a role in
early stages of myelination or that its expression leads to
inhibition of myelination in prenatal stages. The lack of
activation of the JNK pathway may lead to early activation
of myelination, which would lead to early, aberrant my-
elination. This hypothesis is consistent with the obser-
vation that the patients present with an early-onset form
of CMT with slow progression. Moreover, it has been re-
cently demonstrated that, whereas JNK is present through-
out the cell, activated phosphorylated JNK is enriched in
the axon throughout development.52 Therefore, with con-
sideration of the close relationship between axons and
Schwann cells, the Lebanese mutation in FGD4 might af-
fect myelination through the axon.
In this study, we show that the truncated protein re-
sulting from the Lebanese splicing mutation, if produced,
lacks its two PH and FYVE domains, interacting respectively
with phosphatidylinositol(3,4,5)P3 (PtdIns(3,4,5)P3) and
phosphatidylinositol3P (PtdIns3P). These phospholipids
are rare components of membranes and have a role in
recruiting proteins to membranes for signal transduction
and membrane trafficking as well as for cytoskeleton reg-
ulation and apoptosis.49 All these functions might be af-
fected by the mutations found in FGD4. Particularly, it has
been described that the signals that affect myelination
arising from axons in response to the binding of nerve
growth factor to axonal TrkA receptors might involve PI3K
and polyphosphoinositides.53 Moreover, MTMR2 and
MTMR13, two members of a large family of tyrosine/dual
phosphatases, are mutated in CMT4B19 and CMT4B2,12
respectively. These proteins dephosphorylate PtdIns3P
and PtdIns3,5P2, which are notably involved in vacuolar
transport and membrane trafficking, and recent observa-
tions on myotubularin homologues in the nematode Cae-
norhabditis elegans indicate a role in endocytosis.54 FGD4
might consequently be involved in a signaling pathway
involving the myotubularins mutated in other forms of
CMT.
As previously reported for CTDP1, in which a mutation
lying 389 bp downstream of the donor splice site is re-
sponsible for the syndromic neuropathy CCFDN,55 we ob-
served the persistence of the mutated full-length transcript
in the fibroblasts and lymphoblasts of the Lebanese pa-
tients, even though the mutation is homozygous in pa-
tients (fig. 3A). This result suggests that the splice muta-
tion might induce a partial use of the created splicing site
and thus explain the clinical intrafamilial heterogeneity
observed in the Lebanese family.26 However, the signifi-
cant reduction in FGD4 expression level evidenced by
RTQ-PCR in the Lebanese patient’s cells indicates that the
truncated mRNA might be degraded through NMD and
that the protein might not be produced. Moreover, FGD4
expression levels in the patient’s peripheral nerve showed
a complete absence of the full-length transcript (fig. 3A),
consistent with a loss-of-function mutation severely af-
fecting the function of FRABIN, at least in peripheral nerve
tissues.
More than 85 GEFs for Rho GTPases have been iden-
tified to date,34 and several genes encoding Rho GEFs
have been involved in human genetic disorders mainly
affecting the CNS or peripheral nervous system. As par-
adigms, mutations in FGD1 (GenBank accession number
NP_004454) and ARHGEF6 (PIX) cause Aarskog syn-
drome56 and MRX46,57 respectively, two X-linked mental
retardation syndromes. As well, a mutation in ARHGEF10
has been associated with slowed NCVs, an endophenotype
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Figure 6. A, Confocal images showing cultured rat RT4 schwann cells transfected with expression constructs for GFP, full-length (FL)
Frabin-GFP or truncated Frabin-GFP (see fig. 5). Cells are co-labeled for f-actin (in red); details of membrane structures are magnified
(see insets). Scale bars p 10 mm. B, Diagram showing reduced microspike formation in RT4 cell cultures transfected with truncated
forms of Frabin (Frabin 297 GFP and Frabin 249 GFP) as compared with cultures transfected with Frabin FL GFP (* indicates Pp .03
and ** indicates , as assessed by Student t test).Pp .011
of demyelinating CMT,32 and ALSIN2 (ALS2) is mutated in
juvenile amyotrophic lateral sclerosis58,59 and infantile as-
cending hereditary spastic paralysis.60
Along with Rho GAPs and Rho GDIs, Rho GEFs are in-
volved in cytoskeleton dynamics through Rho GTPases,
the latter having a key role in remodeling actin microfil-
aments, an essential step for many cell mechanisms, in-
cluding shape, adhesion, and migration.34,35
Using overexpression of normal and truncated forms of
Frabin in embryonic rat spinal motoneurons and rat RT4
schwannoma cells, we show here that cells transfected
with expression vectors encoding wild-type rat Frabin co-
localize with F-actin in neurite tips and growth cones, in
line with previous data obtained in other cell types,36,37,
43,44 and induce the formation of filopodia-like micro-
spikes, whereas cells expressing the truncated forms of
Frabin still colocalize with F-actin but induce significantly
fewer microspikes than does full-length Frabin. Similar re-
sults were observed in rat RT4 schwannoma cells, in which
the expression of wild-type full-length Frabin induced for-
mation of microspikes, whereas the expression of trun-
cated Frabin significantly inhibited this effect. These data,
together with the known requirement of the FAB, DH, and
PH domains for microspike formation,37,42,43,61,62 strongly
suggest that the p.Met298fsX8 mutation causes disease
through a loss-of-function mechanism.
As previously said, FRABIN is a GEF specific to Cdc42,
a Rho GTPase involved in the reorganization of actin mi-
crofilaments but also the microtubule cytoskeleton.34,45
However, we could not evidence any significant abnor-
malities of the microfilaments or in the distribution and
organization of the microtubules and centrosomes. This
may be explained by the fact that the full-length mutated
transcript persisted in the patient’s fibroblasts, whereas
only the truncated transcript persisted in the patient’s pe-
ripheral nerves. Moreover, several studies have demon-
strated that the roles of FRABIN vary from one cell type
to another,36,37,43,44 specifically with respect to which Rho
GTPases (Cdc42, Rac, and/or Rho) are indirectly activated
and their interrelationships in specific cell types. It is thus
likely that FGD4 mutations have different effects in dif-
ferent cell types, and, in particular, that Schwann cells
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Figure 7. Labeling of microfilament and microtubule cytoskeleton and centrosomes in the control and Lebanese patient (500.21)
fibroblasts (see fig. 1). A, Labeling of microfilament (antibody to F-actin) and microtubules (antibody to a-tubulin). No significant
differences were observed between the control and patient fibroblasts. B, Labeling of total microtubules (antibody to a-tubulin) and
stable microtubules (antibody to acetylated a-tubulin). Stabilized microtubules were denser at centrosomes, but no structural difference
was noticed in patients compared with controls. C, Labeling of centrosome with use of antibody to g-tubulin or pericentrin and antibody
to a-tubulin. Centrosome position and structure seemed normal in both patient and control fibroblasts.
and neurons must be more severely affected. Finally, the
affinity of FRABIN for Cdc42 was shown to be weak in
comparison with other GEFs such as Dbl.37 Consequently,
we cannot exclude the possibility that FGD4 mutations
have a weak impact on Cdc42 activation and cytoskeleton
organization and that FRABIN instead activates other
GTPases and possibly GTPases already known to be in-
volved in CMT diseases, such as MFN2,29 DNM2,30 or
RAB7.31
Together, our results demonstrate that mutations in
FGD4 cause CMT4H, a rare AR-CMT disease. FRABIN is the
sixth protein (after MFN2,29 DNM2,30 RAB7,31 ARHGEF10,32
and SEPT933) related to GTPase signaling but the first Rho
GEF to be identified in CMT disease. It is noteworthy that
several mechanisms and pathways leading to the pathol-
ogy remain to be elucidated. However, taking into account
the structure and function of FRABIN, as well as the pre-
dicted effects of the identified mutations, several hypoth-
eses can be postulated. First, disorganization of the actin/
microtubule cytoskeleton might perturb cell division, po-
larity, and migration and the ensheathment processes by
Schwann cells, as well as microtubule-driven mRNA trans-
port in Schwann cells or axons.53 Second, loss of activation
of the JNK pathways could lead to an aberrant myelination
process in Schwann cells.51 Third, various signaling path-
ways mediated by polyphosphoinositides—in particular,
Schwann cell-axon communications—might be damaged.
Overall, FRABIN could play a key role in the proliferation,
polarization, and survival of Schwann cells and myeli-
nation processes. Like myotubularins, a family of proteins
with members found to be mutated in CMT subtypes,9,12
FRABIN seems to be involved in polyphosphoinositide sig-
naling. The identification of FRABIN as a new defective
protein in CMT disease is thus a major stimulus for efforts
aimed at a better understanding of the pathophysiology
of these diseases, as well as the relationships between the
Schwann cell and the axon. The identification of the un-
derlying pathogenic mechanisms is under way and, we
hope, will provide useful insights into the functional re-
lationships between the different proteins involved in
CMT disease.
14 The American Journal of Human Genetics Volume 81 July 2007 www.ajhg.org
Acknowledgments
We express our sympathy to the families and gratitude for their
full cooperation throughout the study. The authors thank San-
drine Peireira and Daniele Depetris for excellent technical assis-
tance, Marie-Christine Lebart for assistance in the production of
a rabbit polyclonal antibody to FRABIN, Prof. Ge´rard Lefranc for
constant support and logistics, Prof. Pierre Cau for helpful com-
ments and criticisms during the study, and Dr. Mike Mitchell for
English revisions of this manuscript. We are grateful to Prof. Ol-
iver Hanneman, who kindly provided RT4 schwannoma cell lines,
and to Prof. Y. Takai for sharing rat Frabin constructs. We are
extremely grateful to Prof. Ruti Parvari and Dina Aranovic for
their help in cytoskeleton explorations. This work was financially
supported by the Network for Rare Diseases (GIS maladies rares),
the Association Franc¸aise contre les Myopathies (AFM), the Ag-
ence Universitaire de la Francophonie, and INSERM. T.H. is sup-
ported by a grant from AFM.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
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